In this issue: Investor Q&A; Implications of the Leahy-Smith America Invents Act for Chinese Life Science Companies; Frequent Issues Arising in Acquisitions of China Life Sciences Targets; and Key Regulatory Development.
Welcome to the inaugural issue of our China Life Sciences Newsletter, a periodic update on key developments, companies and people in the dynamic China life sciences industry. The goal of the newsletter is to provide companies, entrepreneurs and investors with useful information on the issues and opportunities most relevant to China life sciences businesses.
Our issue opens with an Investor Q&A piece with Dr. Leon Chen of Fidelity Growth Partners Asia. Dr. Chen’s experience spans the research laboratory, management consulting, and most recently, life sciences venture capital industries. Dr. Chen reviews notable trends and opportunities in the med device sector in China. Next is an article by a Morrison & Foerster patent partner Peng Chen addressing implications of the Leahy-Smith America Invents Act specifically for Chinese life science companies, including the need to reevaluate patent application filing strategies and policies regarding public disclosure of inventions in view of the shift to first-to-file, and amendments to the test for what is considered prior art under U.S. patent law. Finally, we also feature in this inaugural issue an article highlighting key points to consider when acquiring a Chinese life sciences company, and a brief note on regulatory developments of interest.
Please see full publication below for more information.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.